Technology

MV BioTherapeutics has developed modified microorganisms that have different characteristics and a unique potential in a wide range of Pharma and Animal Health indications

MV BioTherapeutics ApyraVax

ApyraVax is a technology platform for live attenuated oral vaccines eliciting protective mucosal responses against enteric pathogens. The first application is a vaccine for Clostridioides difficile infection, a disease that is causing hundreds of thousands of casualties every year and generating huge medical costs.

MV BioTherapeutics ApyraMed

ApyraMed is a live biotherapeutic that has been validated in pre-clinical studies as immune modulator in cancer patients and intestinal dysbiosis.

We aim at completing Phase II clinical trials with our lead candidates to license products thereafter. Nevertheless, we consider licensing negotiations at any stage.